Affymax CMO joins California stem cell agency board
This article was originally published in Clinica
Dr Anne-Marie Duliege, chief medical officer of Affymax, has been appointed to the board of the Independent Citizens Oversight Committee, the governing board of California's stem cell agency, the California Institute for Regenerative Medicine.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.